Skip to main content
. 2022 Oct 28;54(6):1112–1116. [Article in Chinese] doi: 10.19723/j.issn.1671-167X.2022.06.009

表 2.

不同剂量环磷酰胺不良反应发生率的比较

Adverse effects of SILD IV-CYC and HD IV-CYC treatment in SLE patients

Adverse events Patients(n=762) SILD IV-CYC (n=506) HD IV-CYC (n=256) P values
n % n % n %
Data were presented as count (percentage). * P < 0.05. a, a total of 423 female patients aged between 16 and 45 were included in 762 patients with SLE; b, a total of 282 female patients with age between 16 and 45 were included in SILD IV-CYC group; c, a total of 141 female patients with age between 16 and 45 were included in HD IV-CYC group. SILD IV-CYC, short-interval low-dose intravenous cyclophosphamide; HD IV-CYC, high-dose intravenous cyclophosphamide; SLE, systemic lupus erythematosus.
Infection 123 16.14 66 13.04 57 22.27 0.001*
Gastrointestinal reaction 168 22.05 88 17.39 80 31.25 < 0.001*
Myelosuppression 100 13.12 49 9.68 51 19.92 < 0.001*
Abnormal menstruation 127a 30.02 71b 25.18 56c 39.72 0.001*
Drug-induced hepatic injury 46 6.04 27 5.34 19 7.42 0.253
Hemorrhagic cystitis 4 0.52 3 0.59 1 0.39 1.000
Fatigue 46 6.04 33 6.52 13 5.08 0.429
Alopecia 117 15.35 68 13.44 49 19.14 0.039*
Rash 12 1.57 10 1.98 2 0.78 0.355